SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Accounts Payable of -$1.53 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2020-11-06
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2020-09-30 was $5.67M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2020-06-30 was -$182.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2020-03-31 was -$7.02M, a 273.47% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2019-12-31 was $7.30M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2019 was $6.96M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2018 was -$3.58M.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2017 was -$620.00K, a 117.87% decline from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2016 was $3.47M, a 68.36% increase from fiscal 2015.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2020-09-30 | $5.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $5.49M derived: sum of 2 quarters · filed 2020-11-06 | -$1.53M 10-Q · filed 2020-11-06 | $5.77M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2020-06-30 | -$182.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | -$7.20M 10-Q · filed 2020-08-17 | $97.00K derived: sum of 3 quarters · filed 2020-08-17 | -$1.12M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2020-03-31 | -$7.02M 10-Q · filed 2020-05-15 | $279.00K derived: sum of 2 quarters · filed 2020-05-15 | -$941.00K derived: sum of 3 quarters · filed 2020-11-06 | -$4.10M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2019-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $6.08M derived: sum of 2 quarters · filed 2020-11-06 | $2.92M derived: sum of 3 quarters · filed 2020-11-06 | $6.96M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$4.38M derived: sum of 2 quarters · filed 2020-11-06 | -$334.00K 10-Q · filed 2020-11-06 | -$6.98M derived: sum of 4 quarters · filed 2020-11-06 | |||
| 2019-06-30 | -$3.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-17 | $886.00K 10-Q · filed 2020-08-17 | -$5.76M derived: sum of 3 quarters · filed 2020-08-17 | $1.15M derived: sum of 4 quarters · filed 2020-08-17 | |||
| 2019-03-31 | $4.04M 10-Q · filed 2020-05-15 | -$2.60M derived: sum of 2 quarters · filed 2020-05-15 | $4.30M derived: sum of 3 quarters · filed 2020-05-15 | $3.91M derived: sum of 4 quarters · filed 2020-05-15 | |||
| 2018-12-31 | -$6.64M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $260.00K derived: sum of 2 quarters · filed 2020-02-28 | -$138.00K derived: sum of 3 quarters · filed 2020-02-28 | -$3.58M 10-K · filed 2020-02-28 | |||
| 2018-09-30 | $6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $6.51M derived: sum of 2 quarters · filed 2019-11-08 | $3.07M 10-Q · filed 2019-11-08 | $3.76M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-06-30 | -$398.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$3.84M 10-Q · filed 2019-08-09 | -$3.15M derived: sum of 3 quarters · filed 2020-02-28 | -$4.51M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-03-31 | -$3.44M 10-Q · filed 2019-05-10 | -$2.75M derived: sum of 2 quarters · filed 2020-02-28 | -$4.11M derived: sum of 3 quarters · filed 2020-02-28 | -$927.00K derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2017-12-31 | $692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$670.00K derived: sum of 2 quarters · filed 2020-02-28 | $2.51M derived: sum of 3 quarters · filed 2020-02-28 | -$620.00K 10-K · filed 2020-02-28 | |||
| 2017-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $1.82M derived: sum of 2 quarters · filed 2018-11-09 | -$1.31M 10-Q · filed 2018-11-09 | $3.79M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-06-30 | $3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $50.00K 10-Q · filed 2018-08-09 | $5.15M derived: sum of 3 quarters · filed 2019-03-01 | $5.59M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2017-03-31 | -$3.13M 10-Q · filed 2018-05-10 | $1.97M derived: sum of 2 quarters · filed 2019-03-01 | $2.41M derived: sum of 3 quarters · filed 2019-03-01 | $2.03M derived: sum of 4 quarters · filed 2019-03-01 | |||
| 2016-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $5.54M derived: sum of 2 quarters · filed 2019-03-01 | $5.16M derived: sum of 3 quarters · filed 2019-03-01 | $3.47M 10-K · filed 2019-03-01 | |||
| 2016-09-30 | $442.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $62.00K derived: sum of 2 quarters · filed 2017-11-09 | -$1.63M 10-Q · filed 2017-11-09 | -$517.00K derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-06-30 | -$380.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$2.07M 10-Q · filed 2017-08-03 | -$959.00K derived: sum of 3 quarters · filed 2018-03-01 | -$1.87M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2016-03-31 | -$1.69M 10-Q · filed 2017-05-09 | -$579.00K derived: sum of 2 quarters · filed 2018-03-01 | -$1.49M derived: sum of 3 quarters · filed 2018-03-01 | $1.37M derived: sum of 4 quarters · filed 2018-03-01 | |||
| 2015-12-31 | $1.11M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $199.00K derived: sum of 2 quarters · filed 2018-03-01 | $3.06M derived: sum of 3 quarters · filed 2018-03-01 | $2.06M 10-K · filed 2018-03-01 | |||
| 2015-09-30 | -$913.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-01-20 | $1.95M derived: sum of 2 quarters · filed 2017-01-23 | $949.00K 10-Q/A · filed 2017-01-20 | $479.00K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | $2.87M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-01-23 | $1.86M 10-Q/A · filed 2017-01-23 | $2.65M 10-Q · filed 2015-08-07 | $1.39M derived: sum of 3 quarters · filed 2017-03-16 | $1.14M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-03-31 | -$1.00M 10-Q/A · filed 2017-01-20 | -$1.47M derived: sum of 2 quarters · filed 2017-03-16 | -$1.73M derived: sum of 3 quarters · filed 2017-03-16 | -$2.08M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$470.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | -$725.00K derived: sum of 2 quarters · filed 2017-03-16 | -$1.08M derived: sum of 3 quarters · filed 2017-03-16 | -$2.05M 10-K · filed 2017-03-16 | -$1.28M 10-K · filed 2015-03-12 | ||
| 2014-09-30 | -$255.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2017-01-20 | -$609.00K derived: sum of 2 quarters · filed 2017-01-20 | -$1.58M 10-Q/A · filed 2017-01-20 | $1.57M 10-Q · filed 2015-11-09 | |||
| 2014-06-30 | -$354.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$1.33M 10-Q · filed 2015-08-07 | |||||
| 2014-03-31 | -$975.00K 10-Q · filed 2015-05-06 | ||||||
| 2013-12-31 | $336.00K 10-K/A · filed 2017-01-20 | ||||||
| 2012-12-31 | $318.00K 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |